GEP20033053B - Substituted Pyrazoles as P38 Kinase Inhibitors, Methods for their Production, Pharmaceutical Compositions Containing Them and Methods for Treatment - Google Patents

Substituted Pyrazoles as P38 Kinase Inhibitors, Methods for their Production, Pharmaceutical Compositions Containing Them and Methods for Treatment

Info

Publication number
GEP20033053B
GEP20033053B GEAP19985095A GEAP1998005095A GEP20033053B GE P20033053 B GEP20033053 B GE P20033053B GE AP19985095 A GEAP19985095 A GE AP19985095A GE AP1998005095 A GEAP1998005095 A GE AP1998005095A GE P20033053 B GEP20033053 B GE P20033053B
Authority
GE
Georgia
Prior art keywords
methods
treatment
production
pharmaceutical compositions
compositions containing
Prior art date
Application number
GEAP19985095A
Other languages
English (en)
Inventor
K Khana Ish
Xiangdong Xu
Michael A Stealey
Shashidhar N Rao
Shuyuan Liao
Gunnar J Hanson
Daniel L Flynn
Joyce Zuowu Crich
Michael Clare
Iu Ii
Richard M Weier
Michael S South
Shaun Raj Selness
Richard A Partis
Francis J Koszyk
Lifeng Geng
Rajesh Devraj
Paul W Collins
Ashok Anantanarayan
Original Assignee
Searle & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Searle & Co filed Critical Searle & Co
Publication of GEP20033053B publication Critical patent/GEP20033053B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
GEAP19985095A 1997-05-22 1998-05-22 Substituted Pyrazoles as P38 Kinase Inhibitors, Methods for their Production, Pharmaceutical Compositions Containing Them and Methods for Treatment GEP20033053B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4757097P 1997-05-22 1997-05-22

Publications (1)

Publication Number Publication Date
GEP20033053B true GEP20033053B (en) 2003-08-25

Family

ID=21949743

Family Applications (1)

Application Number Title Priority Date Filing Date
GEAP19985095A GEP20033053B (en) 1997-05-22 1998-05-22 Substituted Pyrazoles as P38 Kinase Inhibitors, Methods for their Production, Pharmaceutical Compositions Containing Them and Methods for Treatment

Country Status (24)

Country Link
EP (1) EP1000055A1 (id)
JP (1) JP2002508754A (id)
KR (1) KR20010012854A (id)
CN (1) CN1264377A (id)
AP (1) AP1246A (id)
AU (1) AU754830C (id)
BG (1) BG64313B1 (id)
BR (1) BR9809147A (id)
CA (1) CA2291115A1 (id)
EA (1) EA003925B1 (id)
EE (1) EE9900527A (id)
GE (1) GEP20033053B (id)
HU (1) HUP0001880A3 (id)
ID (1) ID22982A (id)
IL (1) IL132991A (id)
IS (1) IS5257A (id)
NO (1) NO995695L (id)
NZ (1) NZ501112A (id)
OA (1) OA12981A (id)
PL (1) PL337020A1 (id)
SK (1) SK157899A3 (id)
TR (1) TR200000235T2 (id)
WO (1) WO1998052940A1 (id)
ZA (1) ZA984358B (id)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW289752B (id) * 1994-03-11 1996-11-01 Ciba Geigy Ag
US5559137A (en) * 1994-05-16 1996-09-24 Smithkline Beecham Corp. Compounds
AU7726898A (en) 1997-05-22 1998-12-11 G.D. Searle & Co. Pyrazole derivatives as p38 kinase inhibitors
US6514977B1 (en) 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
US6979686B1 (en) 2001-12-07 2005-12-27 Pharmacia Corporation Substituted pyrazoles as p38 kinase inhibitors
CA2294057A1 (en) 1997-06-13 1998-12-17 Smithkline Beecham Corporation Novel pyrazole and pyrazoline substituted compounds
US7301021B2 (en) 1997-07-02 2007-11-27 Smithkline Beecham Corporation Substituted imidazole compounds
US6858617B2 (en) 1998-05-26 2005-02-22 Smithkline Beecham Corporation Substituted imidazole compounds
US6184226B1 (en) * 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
CA2346665A1 (en) 1998-10-07 2000-04-13 Smithkline Beecham Corporation Novel treatment for stroke management
WO2000025791A1 (en) 1998-11-04 2000-05-11 Smithkline Beecham Corporation Pyridin-4-yl or pyrimidin-4-yl substituted pyrazines
WO2000035911A1 (en) 1998-12-16 2000-06-22 Aventis Pharma Limited Heteroaryl-cyclic acetals
US6191147B1 (en) * 1998-12-24 2001-02-20 Ppd Discovery, Inc. Pyrazole compounds and uses thereof
AU765492B2 (en) * 1998-12-25 2003-09-18 Teikoku Hormone Mfg. Co., Ltd. Aminopyrazole derivatives
CA2368631A1 (en) 1999-03-26 2000-10-05 Euro-Celtique S.A. Aryl substituted pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles, and the use thereof
CN1178931C (zh) 1999-06-03 2004-12-08 帝国脏器制药株式会社 取代吡唑化合物
US7122666B2 (en) 1999-07-21 2006-10-17 Sankyo Company, Limited Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses
MXPA02001565A (es) * 1999-08-13 2005-07-14 Vertex Pharma Inhibidores de cinasas c-jun n-terminal (jnk) y de otras cinasas proteicas.
AU7922100A (en) * 1999-10-25 2001-05-08 Basf Aktiengesellschaft Agrochemical compositions containing pyrazoles as the active agents and use of said compositions as plant protection agents with a fungicidal action
DE19952147A1 (de) 1999-10-29 2001-05-03 Boehringer Ingelheim Pharma Neue Cyclopropane, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
EP1233951B1 (en) 1999-11-23 2005-06-01 SmithKline Beecham Corporation 3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p38 kinase inhibitors
AU1781601A (en) 1999-11-23 2001-06-04 Smithkline Beecham Corporation 3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p38 kinase inhibitors
ATE305787T1 (de) 1999-11-23 2005-10-15 Smithkline Beecham Corp 3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p39-kinase-inhibitoren
US7235551B2 (en) 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
DK1309592T3 (da) 2000-08-14 2006-08-21 Ortho Mcneil Pharm Inc Substituerede pyrazoler
GB0102687D0 (en) 2001-02-02 2001-03-21 Pharmacia & Upjohn Spa Oxazolyl-pyrazole derivatives active as kinase inhibitors,process for their preparation and pharmaceutical compositions comprising them
CA2437248A1 (en) * 2001-02-02 2002-08-15 Takeda Chemical Industries, Ltd. Jnk inhibitor
US7074801B1 (en) 2001-04-26 2006-07-11 Eisai Co., Ltd. Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof
EP1397364B1 (en) 2001-05-24 2007-07-25 Eli Lilly And Company Novel pyrrole derivatives as pharmaceutical agents
US7057049B2 (en) 2001-09-25 2006-06-06 Pharmacia Corporation Process for making substituted pyrazoles
KR100697482B1 (ko) 2001-09-25 2007-03-20 파마시아 코포레이션 치환된 피라졸의 제조 방법
RU2277534C2 (ru) * 2001-09-25 2006-06-10 Фармация Корпорейшн Способ получения замещенных пиразолов
US20040082551A1 (en) * 2002-06-05 2004-04-29 Benson Alan G. Novel pyrazoles and their use as p38 kinase inhibitors
GB0215844D0 (en) 2002-07-09 2002-08-14 Novartis Ag Organic compounds
DE60310730T2 (de) 2002-07-09 2007-05-16 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische zusammensetzungen aus anticholinergica und p38 kinase hemmern zur behandlung von erkrankungen der atemwege
GB0217786D0 (en) * 2002-07-31 2002-09-11 Glaxo Group Ltd Compounds
EP1534680B1 (en) 2002-08-14 2012-02-22 Pharmaco Investments, Inc. Prenylation inhibitors and methods of their synthesis and use
US6649638B1 (en) 2002-08-14 2003-11-18 Ppd Discovery, Inc. Prenylation inhibitors and methods of their synthesis and use
WO2004026302A1 (en) * 2002-09-19 2004-04-01 Eli Lilly And Company Methods of inhibiting tgf beta with substituted pyrazoles
GB0229618D0 (en) * 2002-12-19 2003-01-22 Cancer Rec Tech Ltd Pyrazole compounds
KR20050096956A (ko) 2003-02-07 2005-10-06 다이이찌 세이야꾸 가부시기가이샤 피라졸 유도체
US20060035893A1 (en) 2004-08-07 2006-02-16 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
PL1778686T3 (pl) 2004-08-12 2009-04-30 Pfizer Pochodne triazolopirydynylosulfanylowe jako inhibitory kinazy MAP P38
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
AU2005320544B2 (en) 2004-12-28 2011-03-24 Aska Pharmaceutical Co., Ltd. Pyrimidinylisoxazol derivative
EP2024353A2 (en) * 2006-03-16 2009-02-18 Pfizer Products Inc. Pyrazole compounds
EP2036905B1 (en) 2006-06-28 2012-12-12 ASKA Pharmaceutical Co., Ltd. Pyridylisoxazole derivative
WO2008001929A1 (en) * 2006-06-28 2008-01-03 Aska Pharmaceutical Co., Ltd. Treatment agent for inflammatory bowel disease
US8309138B2 (en) 2007-02-16 2012-11-13 Aska Pharmaceutical Co., Ltd. Pharmaceutical composition comprising microparticle oily suspension
EP1992344A1 (en) 2007-05-18 2008-11-19 Institut Curie P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation
US20100144756A1 (en) * 2007-07-13 2010-06-10 Bolea Christelle Novel heteroaromatic derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors
CL2008003407A1 (es) 2007-11-16 2010-01-11 Boehringer Ingelheim Int Compuestos derivados de aril- y heteroarilcarbonilo de heterobiciclo sustituido; composicion farmaceutica; procedimiento de preparacion; y su uso en el tratamiento y/o prevencion de trastornos metabolicos, mediado por la inhibicion de la enzima hsd-1.
CL2009000904A1 (es) * 2008-04-21 2010-04-30 Shionogi & Co Compuestos derivados de ciclohexil sulfonamidas que tienen actividad antagonista en el receptor npy y5, composicion farmaceutica y formulacion farmaceutica que los comprende.
US8765780B2 (en) 2008-05-13 2014-07-01 Boehringer Ingelheim International Gmbh Alicyclic carboxylic acid derivatives of benzomorphans and related scaffolds, medicaments containing such compounds and their use
SI2324008T1 (sl) 2008-07-24 2012-08-31 Nerviano Medical Sciences Srl 3,4-diarilpirazoli kot protein-kinazni inhibitorji
CA2735204C (en) * 2008-08-25 2017-06-20 Boehringer Ingelheim International Gmbh Aryl- and heteroarylcarbonyl derivatives of substituted nortropanes, medicaments containing such compounds and their use
JP2012506388A (ja) * 2008-10-23 2012-03-15 ロンザ リミテッド 置換されたピラゾールの合成方法
WO2010058858A1 (ja) * 2008-11-21 2010-05-27 ラクオリア創薬株式会社 ５－ｈｔ２ｂ受容体拮抗活性を有する新規ピラゾール－３－カルボキサミド誘導体
WO2010139673A1 (en) 2009-06-02 2010-12-09 Boehringer Ingelheim International Gmbh Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
EP2440537A1 (en) 2009-06-11 2012-04-18 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 based on the 1,3 -oxazinan- 2 -one structure
WO2011023677A1 (en) * 2009-08-26 2011-03-03 Novartis Ag Tetra-substituted heteroaryl compounds and their use as mdm2 and/or mdm4 modulators
JO3002B1 (ar) 2009-08-28 2016-09-05 Irm Llc مركبات و تركيبات كمثبطات كيناز بروتين
EP2308866A1 (de) 2009-10-09 2011-04-13 Bayer CropScience AG Phenylpyri(mi)dinylpyrazole und ihre Verwendung als Fungizide
AR079545A1 (es) 2009-12-21 2012-02-01 Bayer Cropscience Ag Tienilpiri(mi)dinilazol
WO2011092088A1 (en) 2010-01-27 2011-08-04 Nerviano Medical Sciences S.R.L. Sulfonamido derivatives of 3,4-diarylpyrazoles as protein kinase inhibitors
AR081810A1 (es) 2010-04-07 2012-10-24 Bayer Cropscience Ag Piridinilpirazoles biciclicos
US8933072B2 (en) 2010-06-16 2015-01-13 Vitae Pharmaceuticals, Inc. Substituted 5-,6- and 7-membered heterocycles, medicaments containing such compounds, and their use
WO2012016993A1 (en) 2010-08-03 2012-02-09 Nerviano Medical Sciences S.R.L. Derivatives of pyrazolophenyl-benzenesulfonamide compounds and use thereof as antitumor agents
LT3181133T (lt) * 2010-12-20 2019-09-25 Pfizer Inc. Nauji kondensuoti piridino junginiai, kaip kazeino kinazės inhibitoriai
WO2012175513A1 (en) 2011-06-20 2012-12-27 Bayer Intellectual Property Gmbh Thienylpyri(mi)dinylpyrazole
JP2014524438A (ja) 2011-08-17 2014-09-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング インデノピリジン誘導体
RU2627272C2 (ru) 2011-10-06 2017-08-04 Байер Интеллектчуал Проперти Гмбх Гетероциклилпиридинилпиразолы
CN104039785A (zh) 2011-10-06 2014-09-10 拜耳知识产权有限责任公司 作为杀真菌剂的杂环基吡(嘧)啶基吡唑
DE102011115525A1 (de) 2011-10-11 2013-04-11 Boehringer Ingelheim International Gmbh Zweiteilige Flasche mit einem darin angeordneten Trockenmittel
CN108542906A (zh) 2011-11-11 2018-09-18 诺华股份有限公司 治疗增生性疾病的方法
ES2695099T3 (es) 2011-11-23 2019-01-02 Array Biopharma Inc Formulaciones farmacéuticas
ES2900815T3 (es) 2013-03-15 2022-03-18 Scripps Research Inst Compuestos y métodos para inducir la condrogénesis
WO2015088038A1 (ja) * 2013-12-12 2015-06-18 住友化学株式会社 芳香族化合物及びその用途
CN104829536B (zh) * 2015-05-04 2017-12-29 陕西科技大学 一种具抗肿瘤活性的苯基吡唑羧酸类化合物及其合成方法
JP6746614B2 (ja) * 2015-05-27 2020-08-26 杏林製薬株式会社 ウレア誘導体、またはその薬理学的に許容される塩
CN112480005B (zh) * 2017-11-08 2022-08-19 北京嘉林药业股份有限公司 化合物及其治疗癌症的用途
WO2020113094A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
WO2020124397A1 (en) 2018-12-19 2020-06-25 Inventisbio Shanghai Ltd. C-terminal src kinase inhibitors
US12479816B2 (en) 2019-02-08 2025-11-25 University of Pittsburgh—of the Commonwealth System of Higher Education 20-HETE formation inhibitors
CA3166630A1 (en) 2020-01-03 2021-07-08 Berg Llc Polycyclic amides as ube2k modulators for treating cancer
EP3978487A1 (en) * 2020-09-30 2022-04-06 Origo Biopharma, S.L. 2-(3-pyridin-2-yl-4-quinolin-4-yl-pyrazol-1-yl)-acetamide derivatives as inhibitors of transforming growth factor-beta receptor i/alk5
EP4271374A4 (en) * 2020-12-29 2025-03-05 Revolution Medicines, Inc. SOS1 INHIBITORS AND USES THEREOF
WO2025231152A1 (en) * 2024-04-30 2025-11-06 The Cleveland Clinic Foundation Compounds and methods for restoring beta-adrenergic receptor function

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2753659B2 (ja) * 1990-09-03 1998-05-20 株式会社大塚製薬工場 ピラゾール誘導体
US5593992A (en) * 1993-07-16 1997-01-14 Smithkline Beecham Corporation Compounds
US5559137A (en) * 1994-05-16 1996-09-24 Smithkline Beecham Corp. Compounds
US5486534A (en) * 1994-07-21 1996-01-23 G. D. Searle & Co. 3,4-substituted pyrazoles for the treatment of inflammation
JP3734180B2 (ja) * 1994-12-28 2006-01-11 エーザイ株式会社 新規ピラゾール誘導体

Also Published As

Publication number Publication date
HUP0001880A3 (en) 2002-03-28
BG64313B1 (bg) 2004-09-30
ZA984358B (en) 1999-05-24
IL132991A0 (en) 2001-03-19
EE9900527A (et) 2000-06-15
IS5257A (is) 1999-11-19
EP1000055A1 (en) 2000-05-17
OA12981A (en) 2006-10-13
AU754830C (en) 2004-02-12
PL337020A1 (en) 2000-07-31
WO1998052940A1 (en) 1998-11-26
AU7588398A (en) 1998-12-11
CN1264377A (zh) 2000-08-23
KR20010012854A (ko) 2001-02-26
NO995695D0 (no) 1999-11-19
NZ501112A (en) 2002-10-25
HUP0001880A2 (en) 2001-03-28
BG103964A (en) 2000-08-31
CA2291115A1 (en) 1998-11-26
JP2002508754A (ja) 2002-03-19
NO995695L (no) 2000-01-21
TR200000235T2 (tr) 2000-05-22
SK157899A3 (en) 2000-08-14
ID22982A (id) 1999-12-23
EA199900953A1 (ru) 2000-10-30
BR9809147A (pt) 2000-08-01
AP1246A (en) 2004-02-07
EA003925B1 (ru) 2003-10-30
AP9901715A0 (en) 1999-12-31
IL132991A (en) 2005-11-20
AU754830B2 (en) 2002-11-28

Similar Documents

Publication Publication Date Title
GEP20033053B (en) Substituted Pyrazoles as P38 Kinase Inhibitors, Methods for their Production, Pharmaceutical Compositions Containing Them and Methods for Treatment
GEP20053421B (en) Substituted Pyrazoles As P38 Kinase Inhibitors, Method for Their Production and Pharmaceutical Compositions Containing Them
GEP20032896B (en) 4-Aminothiazole Derivatives, Containing Them Pharmaceutical Compositions Inhibiting Cyclin-Dependent Kinases and Methods for Treatment
GEP20043269B (en) Purine Derivatives, Method for Their Production and Composition Containing the Same
YU20999A (sh) Heterociklični derivati koji inhibiraju faktor xa
SE0202462D0 (sv) Novel use
AP9701041A0 (en) Pyridylpyrrole compounds.
TNSN06064A1 (en) 5-phenyl-4-methyl-thiazol-2-yl-amine derivatives as inhibitors of phosphatidylinositol 3 kinase enzymes (pi3) for the treatment of inflammatory airway diseases
NZ508268A (en) Bicyclic pyrimidines and bicyclic 3,4- dihydropyrimidines as inhibitors of cellular proliferation
GEP20053530B (en) Tyrosine Kinase Inhibitors, Pharmaceutical Compositions Containing Them and Use Thereof
MY129540A (en) Quinazoline derivatives, pharmaceutical compositions containing them processes for their preparation and their use in the production of an antiangiogenic and/or vascular permeability reducing effect
IL125282A (en) Substituted imidazole compounds, process for their preparation, pharmaceutical compositions containing them and use thereof in the preparation of medicaments for treating cytokine mediated diseases
ATE327225T1 (de) Neue verwendung von benzothiazolderivaten
GEP20063831B (en) Substituted bicyclic derivatives for treatment of abnormal cell growth
MY107157A (en) Quinuclidine derivatives.
YU56192A (sh) Heterociklični derivati
MY123199A (en) Gastrokinetic bicyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives
BG103947A (en) Derivatives of 9-oxymerythromycin
GEP20063751B (en) 2-Acyl Indol Derivatives and Their Use as Anti-Tumour Agents
TW375615B (en) Galanthamine derivatives and their use as medicaments
IL139406A0 (en) Heterocyclic derivatives which inhibit factor xa
IL107287A (en) Heterocyclic derivatives process for their preparation and pharmaceutical compositions containing some of them
NZ524742A (en) Bridged piperazine derivatives
DE69413118D1 (de) Benzolsulfonamid-Derivate zur Behandlung der Blaseninstabilität
AU3620799A (en) Heterocyclic derivatives which inhibit factor xa